Drug firm Wockhardt today said the UK health regulator MHRA has completed inspection of its plant at Chikalthana in Maharashtra without issuing any critical observations on the facility.
The inspection of the company's manufacturing unit at Chikalthana, Aurangabad by the UK Medicines and Healthcare products Regulatory Agency (MHRA) has been completed and there were no critical observations, Wockhardt Ltd said in a filing to the BSE.
Earlier this year, the US Food and Drug Administration (USFDA) had also not found any issues with respect to data security and control measures at the Mumbai-based drug maker's Chikalthana plant, but suggested continuous voluntary compliance for "desired quality culture".
In November 2013, USFDA had imposed restrictions on import of medicines produced at the company's Chikalthana plant due to non-compliance of good manufacturing practice.
Wockhardt shares today ended at Rs 1,541.15 apiece on the BSE, up 1.05 per cent from previous close.
